Open access · CC-BY
via OpenAlex
Rapamycin for the aging skin
Aging · 2019 · ▲ 14 citations
Deregulated nutrient-sensing
Cellular senescence
Stem-cell exhaustion
Altered intercellular communication
Rapamycin / mTOR inhibition
Human
Abstract
In 2007, I filed a patent application claiming that topical mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (e.g., in the form of a cream or ointment) https://patents.google.com/patent/WO2008022256A2/encould be used to prevent and treat skin aging.Potential indications include various types of age-related spots, wrinkles, photo-aged skin, and other age-related skin conditions.The patent was not granted, nor were cosmetic companies interested in pursuing this avenue of product development.Cell senescence(definition) has traditionally been seen as growth arrest.It seemed weird that rapamycin, a drug that inhibits growth, could inhibit cellular senescence.Nonetheless, it works because, actually, senescence is a continuation of growth when true growth is impossible [1]; in other words, senescence is "twisted" growth [2].In an exciting 'twist', these claims were recently confirmed in a clinical trial by Chung et al. [3], which I will discuss later.Even in 2007, the idea of using rapamycin topically was not novel [4,5].(What was novel in my application was the idea of using topical rapamycin as an anti-aging drug for the aging skin [1]).By now, there have been dozens of papers describing the therapeutic use of rapamycin (Sirolimus) in patients with such skin diseases as lymphatic malformations, vascular anomalies, Facial Angiofibroma and psoriasis [6][7][8][9][10][11][12][13].These diseases were treated in children and young adults.In one study, topical rapamycin at low doses (0.003-0.015%) decreased facial angiofibromas in young adults.There was no systemic absorption of rapamycin (blood levels were <1.0 ng/mL) [13].Returning to cellular senescence, signaling in the mTOR (Target of Rapamycin) pathway drives growth of cellular mass and sustains cell cycle progression.Cells grow and divide, balancing growth.But when the cell cycle is suddenly blocked by p16 or p21, mTOR drives growth-like conversion from reversible arrest (quiescence) to senescence [2,14].In short, mTOR drives geroconversion [15].Rapamycin and its analogs, as well as pan-mTOR inhibitors, suppress geroconversion, thereby maintaining cells in a young healthy state.Moreover, these drugs prevent loss of cells' proliferative potential, which is considered a strict definition of senescence [2,15].Geroconversion in stem cells leads to stem cells depletion [16,17].mTORdriven hypertrophy can be followed by atrophy at the end stages.Cellular hyperfunction eventually leads to cellular exhaustion and secondary functional decline [1].www.aging-us.comAGING 2019, Vol.11, No. 24 Rapamycin for the aging skin
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.102664
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Blagosklonny, M.V. (2019). Rapamycin for the aging skin. <em>Aging</em>. https://doi.org/10.18632/aging.102664
Vancouver
Blagosklonny MV. Rapamycin for the aging skin. Aging. 2019. doi:10.18632/aging.102664.
BibTeX
@article{mikhail2019Rapamy,
title = {Rapamycin for the aging skin},
author = {Mikhail V. Blagosklonny},
journal = {Aging},
year = {2019},
doi = {10.18632/aging.102664},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2011
Preprint · CC-BY
Chronological lifespan in stationary culture: from yeast to human cells
Aging Cell 2013
Open access · CC-BY
TORC 1 signaling inhibition by rapamycin and caffeine affect lifespan, global gene expression, and cell proliferation of fission yeast
Cell Cycle 2010
Open access · OA
Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program
Cancer Biology & Therapy 2012
Open access · OA
Rapalogs in cancer prevention
Cell Cycle 2022
Open access · CC-BY
Cell senescence, rapamycin and hyperfunction theory of aging
Biology 2026
Open access · OA